Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2024 | The potential of immunotherapies in the myeloma treatment landscape

Monique Minnema • 2 Jun 2024
ASCO 2024
Multiple Myeloma Antibodies

Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, highlights how immunotherapies, including bispecifics, trispecifics, NK cell-based therapies, and CAR T-cell therapies, are the most promising ongoing developments in the treatment landscape for multiple myeloma. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

All paid to institution; Beigene, Jansen Cilag, GSK, CDR, BMS, Siemens, Binding Site.

More from Monique Minnema

Bing-Neel syndrome: a rare form of Waldenström’s macroglobulinemia 2:25
Bing-Neel syndrome: a rare form of Waldenström’s macroglobulinemia
Monique Minnema • 13 Nov 2024
Treating Bing-Neel syndrome: chemotherapy and BTK inhibitors 4:20
Treating Bing-Neel syndrome: chemotherapy and BTK inhibitors
Monique Minnema • 13 Nov 2024
Diagnosing Bing-Neel syndrome using MRI and lumbar puncture 1:27
Diagnosing Bing-Neel syndrome using MRI and lumbar puncture
Monique Minnema • 13 Nov 2024
Advice for physicians when managing bispecific antibody treatment for patients with myeloma 0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
Monique Minnema • 2 Jun 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals